N-Benzyl-2-[6-(2-chloroacetylamino)-benzothiazol-2-ylsulfanyl]-acetamide;SKLB 163;SKLB163;SKLB-163;Acetamide, 2-[[6-[(2-chloroacetyl)amino]-2-benzothiazolyl]thio]-N-(phenylmethyl)-;SKLB-163, 10 mM in DMSO
SKLB-163 is an orally active Rho GDP-dissociation inhibitor (RhoGDI inhibitor) that suppresses proliferation and migration of tumor cells with high RhoGDI expression, enhances radiosensitivity of tumor cells, and induces cancer cell apoptosis.